Recombinant Human Thymosin Beta 4 for Injection(NL005) for Acute Myocardial Infarction

Citation record

Study start

2026-05-18

NCT number

NCT07586865

Phase

Phase2

Overall status

Not Yet Recruiting

Study type

Interventional

Lead sponsor

Beijing Northland Biotech. Co., Ltd.

Enrollment

189 participants

Conditions

Acute Myocardial Infarction (AMI) · Acute Myocardial Infarction of Anterior Wall · Acute Myocardial Infarction With ST Elevation · Acute Myocardial Infarction of Left Ventricle · Acute Myocardial Infarction With ST Segment Elevation

Interventions

Recombinant Human Thymosin Beta 4 Injection (NL005) (Drug) · Placebo (Drug)

Last updated at source

14 May 2026

Original source

https://clinicaltrials.gov/study/NCT07586865

This page reproduces citation metadata only. Inclusion in the Avion Science research library does not imply endorsement and does not establish the safety, efficacy or intended use of any Avion Science compound. Refer to the original record for complete study information.